RATIONALE: Selective attention toward emotional cues and emotion recognition of facial expressions are important aspects of social cognition. Stress modulates social cognition through cortisol, which acts on glucocorticoid (GR) and mineralocorticoid receptors (MR) in the brain. OBJECTIVES: We examined the role of MR activation on attentional bias toward emotional cues and on emotion recognition. METHODS: We included 40 healthy young women and 40 healthy young men (mean age 23.9 ± 3.3), who either received 0.4 mg of theMR agonist fludrocortisone or placebo. A dot-probe paradigm was used to test for attentional biases toward emotional cues (happy and sad faces). Moreover, we used a facial emotion recognition task to investigate the ability to recognize emotional valence (anger and sadness) from facial expression in four graded categories of emotional intensity (20, 30, 40, and 80 %). RESULTS: In the emotional dot-probe task, we found a main effect of treatment and a treatment × valence interaction. Post hoc analyses revealed an attentional bias away from sad faces after placebo intake and a shift in selective attention toward sad faces compared to placebo. We found no attentional bias toward happy faces after fludrocortisone or placebo intake. In the facial emotion recognition task, there was no main effect of treatment. CONCLUSIONS: MR stimulation seems to be important in modulating quick, automatic emotional processing, i.e., a shift in selective attention toward negative emotional cues. Our results confirm and extend previous findings of MR function. However, we did not find an effect of MR stimulation on emotion recognition.
RCT Entities:
RATIONALE: Selective attention toward emotional cues and emotion recognition of facial expressions are important aspects of social cognition. Stress modulates social cognition through cortisol, which acts on glucocorticoid (GR) and mineralocorticoid receptors (MR) in the brain. OBJECTIVES: We examined the role of MR activation on attentional bias toward emotional cues and on emotion recognition. METHODS: We included 40 healthy young women and 40 healthy young men (mean age 23.9 ± 3.3), who either received 0.4 mg of the MR agonist fludrocortisone or placebo. A dot-probe paradigm was used to test for attentional biases toward emotional cues (happy and sad faces). Moreover, we used a facial emotion recognition task to investigate the ability to recognize emotional valence (anger and sadness) from facial expression in four graded categories of emotional intensity (20, 30, 40, and 80 %). RESULTS: In the emotional dot-probe task, we found a main effect of treatment and a treatment × valence interaction. Post hoc analyses revealed an attentional bias away from sad faces after placebo intake and a shift in selective attention toward sad faces compared to placebo. We found no attentional bias toward happy faces after fludrocortisone or placebo intake. In the facial emotion recognition task, there was no main effect of treatment. CONCLUSIONS: MR stimulation seems to be important in modulating quick, automatic emotional processing, i.e., a shift in selective attention toward negative emotional cues. Our results confirm and extend previous findings of MR function. However, we did not find an effect of MR stimulation on emotion recognition.
Authors: Maggie Lai; Karen Horsburgh; Sung-Eun Bae; Roderick N Carter; Dirk J Stenvers; Jill H Fowler; Joyce L Yau; Celso E Gomez-Sanchez; Megan C Holmes; Christopher J Kenyon; Jonathan R Seckl; Malcolm R Macleod Journal: Eur J Neurosci Date: 2007-03 Impact factor: 3.386
Authors: Aisha L Udochi; Scott D Blain; Tyler A Sassenberg; Philip C Burton; Leroy Medrano; Colin G DeYoung Journal: Cogn Affect Behav Neurosci Date: 2021-10-19 Impact factor: 3.282
Authors: Jan Nowacki; Katja Wingenfeld; Michael Kaczmarczyk; Woo Ri Chae; Ikram Abu-Tir; Christian Eric Deuter; Dominique Piber; Julian Hellmann-Regen; Christian Otte Journal: Neuropsychopharmacology Date: 2020-07-28 Impact factor: 7.853
Authors: Sophie Metz; Woo R Chae; Christian E Deuter; Christian Otte; Katja Wingenfeld Journal: J Psychopharmacol Date: 2021-03-28 Impact factor: 4.153